Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: GlobeNewswire
Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel following failure of checkpoint inhibitors had objective response rate of 38 percent First patient dosed in IOV-COM-202; the first time that Iovance TIL therapy has been administered in a PD-1/PD-L1 naive patient population SAN CARLOS, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updates from ongoing clinical trials including new interim data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and with TIL therapy lifileucel in advanced melanoma. These data will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 31 to June 4, 2019, in Chicago.
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 11/7/24 - Beat
IOVA
Sec Filings
- 11/21/24 - Form 8-K
- 11/14/24 - Form 4
- 11/14/24 - Form SC
- IOVA's page on the SEC website